VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type ... (t simultaneously addresses both appetite...)

VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes

Date:6/8/2009

t simultaneously addresses both appetite and satiety -- the two main mechanisms that impact eating behavior -- in one daily capsule. Qnexa, an investigational drug, is an obesity therapy being developed to address type 2 diabetes as well as obesity. In phase 2 and phase 3 clinical trials to date, Qnexa has demonstrated significant weight loss, glycemic control, and improvement in cardiovascular risk factors.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncerta
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. New Diabetes Drug Shows Promise in Trial
2. Vaporized viral vector shows promise in anti-cancer gene therapy
3. New Survey Shows Americans Strongly Support Guaranteed Dental Coverage in Healthcare Reform
4. Global Testing Shows No Variation in Swine Flu Virus
5. New Study Shows Many U.S. Contact Lens Wearers Do Not Comply With Recommended Replacement Schedules
6. Protein may be strongest indicator of rare lung disease, study shows
7. People who wear rose-colored glasses see more, University of Toronto study shows
8. Computer modeling shows strategies to rein in epidemics need to be retooled for rural populations
9. New study shows people with mental health problems receive inadequate medical care
10. The Killing of George Tiller: Video "Thine Eyes" Shows True Face of Pro-life Movement in the Face of 'Terrorist' Accusations
11. New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography

Post Your Comments:

VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type ...(t simultaneously addresses both appetite...),Health